| Name | Title | Contact Details |
|---|
Since 2001, Regent Surgical Health has led the way in developing and managing successful surgery center partnerships. The ASC model is constantly evolving and Regent positions our facility partners to meet these changing market conditions and succeed. Today, a vast majority of our partnerships are Physician/Hospital Joint Ventures. Our experience has led us to develop proprietary ownership models that give both doctors and hospital administrators what they need to ensure long term clinical and financial success. Our success had earned us a reputation as Joint Venture Specialists. Regent has extensive knowledge of the ASC marketplace. We have found successful financial solutions to increase net revenues rather than using out of network strategies, pioneered new procedures such as spine, cardiology, gastric banding, and knee replacements into the ASC environment, and developed both majority and minority hospital partnerships. At Regent, our track record for successful ASC Turnarounds, De Novos, and Joint Ventures is unmatched.
NotifyMD is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
New Hanover Regional Medical Center is a not-for-profit health care system serving southeastern North Carolina and northeastern South Carolina. A teaching hospital, regional referral center, and Level 2 Trauma Center, NHRMC is dedicated to providing a wide range of health care services. Our mission is Leading Our Community to Outstanding Health, a bold statement that reinforces our goal to reach far beyond the walls of our hospitals and into the communities that rely on us for their care.
MEDNET USA is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla`s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world`s first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics.